Background
tumor, hypoxia, high-grade serous ovarian cancer, aggressive tumors, TNBC, HGSOC, Cancer
HYPOXIA, TUMOR, TRIPLE-NEGATIVE BREAST CANCER, CANCER
According to the Cancer Genome Atlas, aggressive tumors such as high-grade serous ovarian cancer (HGSOC) and triple-negative breast cancer (TNBC) exhibit genomic characteristics associated with deficiencies in the homologous recombination (HR) repair pathway (e.g. BRCA deficiency) [Anti-angiogenic therapy could induce hypoxia in the tumor microenvironment, cause genetic instability and downregulation of BRCA1/2 and lead to HR deficiency, thereby potentiating response to PARP inhibitors [Fuzuloparib (formerly known as fluzoparib) is a novel PARP inhibitor. It has been approved in China as treatment for germline 